510(k) K192376

Simplexa VZV Swab Direct, Simplexa VZV Positive Control Pack by Diasorin Molecular, LLC — Product Code PGI

K192376 is an FDA 510(k) premarket notification submitted by Diasorin Molecular, LLC for the device "Simplexa VZV Swab Direct, Simplexa VZV Positive Control Pack". The FDA issued a decision of Substantially Equivalent on November 26, 2019. The device falls under product code PGI (Herpes Virus (Vzv, Hsv1, Hsv2), Dna Detection Assay For Cutaneous And Mucocutaneous Lesion Samples), a Class II device regulated under 21 CFR 866.3309. Diasorin Molecular, LLC has at least 10 other 510(k) clearances on record.

Clearance Details

Decision
SESE (Substantially Equivalent)
Decision Date
November 26, 2019
Date Received
August 30, 2019
Clearance Type
Traditional
Expedited Review
No
Third Party Review
No

Device Classification

Device Name
Herpes Virus (Vzv, Hsv1, Hsv2), Dna Detection Assay For Cutaneous And Mucocutaneous Lesion Samples
Device Class
Class II
Regulation Number
866.3309
Review Panel
MI
Submission Type

For the qualitative detection and differentiation of VZV, HSV1, HSV2- DNA in cutaneous and mucocutaneous lesion samples from symptomatic patients. The assay is not intended for use with cerebral spinal fluid.